For example, at their current share prices, both Novartis (NYSE: NVS) and Chevron (NYSE: CVX) yield more than 3%. And it also has 20 treatments in mid-stage clinical trials that it estimates could generate more than $1 billion each in annual sales -- assuming they earn regulatory approval -- providing it with plenty of potential avenues for additional growth. And as long as oil prices remain high -- as they are likely to while inflation and supply/demand imbalances persist -- Chevron management could increase the payout at even higher rates.